Summarised, several (pre-)clinical results have indicated that dual pathway inhibition could evade the problem of cross-talk and improve treatment efficacy in PI3K or MAPK pathway driven endometrial cancers. The gene discussed is PIK3CA; the disease is endometrial cancer.